Search research articles
Contact Us
Filters
Showing results (151-160 of 293) with videos related to
Page
of 30
Sort By:
Rheumatology and Therapy
|
September 27, 2023
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Lancet (London, England)
|
June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
The Journal of Rheumatology
|
November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Arthritis Research & Therapy
|
March 28, 2014
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
Joerg Wendler, Gerd R Burmester, Helmut Sörensen, et al.
Arthritis Research & Therapy
|
April 9, 2020
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
Cem Gabay, Gerd R Burmester, Vibeke Strand, et al.
Rheumatology and Therapy
|
October 13, 2022
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Journal of Autoimmunity
|
June 26, 2012
Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity
Imtiaz M Mumtaz, Bimba F Hoyer, Daniel Panne, et al.
RMD Open
|
December 19, 2023
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial
Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Lancet (London, England)
|
August 25, 2004
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, et al.
Acta Neuropathologica
|
April 17, 2021
Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology
Elise Siegert, Akinori Uruha, Hans-Hilmar Goebel, et al.
Page
of 30
Search research articles
Search
Showing results (151-160 of 293) with videos related to
Sort By:
Page
of 30
Rheumatology and Therapy
|
September 27, 2023
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Lancet (London, England)
|
June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
The Journal of Rheumatology
|
November 17, 2017
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, et al.
Arthritis Research & Therapy
|
March 28, 2014
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
Joerg Wendler, Gerd R Burmester, Helmut Sörensen, et al.
Arthritis Research & Therapy
|
April 9, 2020
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
Cem Gabay, Gerd R Burmester, Vibeke Strand, et al.
Rheumatology and Therapy
|
October 13, 2022
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Journal of Autoimmunity
|
June 26, 2012
Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity
Imtiaz M Mumtaz, Bimba F Hoyer, Daniel Panne, et al.
RMD Open
|
December 19, 2023
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial
Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Lancet (London, England)
|
August 25, 2004
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, et al.
Acta Neuropathologica
|
April 17, 2021
Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology
Elise Siegert, Akinori Uruha, Hans-Hilmar Goebel, et al.
Page
of 30